GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Abbreviated name: BTLA
Synonyms: B- and T-lymphocyte attenuator | B- and T-lymphocyte-associated protein | CD272
Compound class:
Endogenous peptide in human, mouse or rat
Comment: BTLA is a negative immunomodulator. Interaction of BTLA with TNFRSF14 (HVEM) constitutes an immune checkpoint which inhibits T cell-mediated immune responses. Dysregulated BTLA expression contributes to immunosuppression and progression of some cancers [3-6] by enabling tumour immune evasion. Immunotherapeutics that block the BTLA-HVEM checkpoint offer potential as anti-tumour agents [8-9]. In the setting of inflammatory diseases anti-BTLA antibodies can induce inhibitory signalling and block T cell activation, thus reducing pro-inflammatory cytokine secretion [1].
Several anti-BTLA monoclonals have been progressed to clinical trials. Examples include: Radanstobart (HFB200603, HiFiBiO; Phase 1 NCT05789069, solid tumours) [2] Zadoprubart (ANB032, AnaptysBio; Phase 2 NCT05935085, atopic dermatitis; terminated due to insufficient efficacy) [1] Venanprubart (LY3361237; development for autoimmune conditions terminated at Phase 2) Tifcemalimab (JS004, icatolimab; Junshi Biosciences for advanced/metaststic solid tumours) [7] GS-0272 (formerly MB272; Phase 1 NCT06031415 for rheumatoid arthritis was terminated).
Species: Human
|
Classification ![]() |
|
| Compound class | Endogenous peptide in human, mouse or rat |
| Ligand families/groups | CD molecules (ligands) |
Synonyms ![]() |
| B- and T-lymphocyte attenuator | B- and T-lymphocyte-associated protein | CD272 |
Gene/Precursor ![]() |
||||||||||
|
Database Links ![]() |
|
| CATH/Gene3D | 2.60.40.10 |
| Ensembl Gene | ENSG00000186265 (Hs) |
| Entrez Gene | 151888 (Hs) |
| GtoPdb PubChem SID | 178101591 |
| Human Protein Atlas | ENSG00000186265 (Hs) |
| UniProtKB | Q7Z6A9 (Hs) |
| Wikipedia | BTLA |